Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. BJU international Soria, F., Black, P. C., Fairey, A. S., Cookson, M. S., Yu, E. Y., Kassouf, W., Dall'Era, M. A., Sridhar, S. S., McGrath, J. S., Wright, J. L., Thorpe, A. C., Morgan, T. M., Daneshmand, S., Holzbeierlein, J. M., Bivalacqua, T. J., North, S., Barocas, D. A., Lotan, Y., Grivas, P., Stephenson, A. J., Shah, J. B., van Rhijn, B. W., Spiess, P. E., Shariat, S. F., Gontero, P. 2020

Abstract

OBJECTIVES: To assess the efficacy of neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) in a retrospective multicenter patient cohort of patients with cT2N0M0 BCa without preoperative hydronephrosis.MATERIALS AND METHODS: This was a propensity-based analysis of 619 patients. Of these, 316 were treated with NAC followed by RC and 303 with upfront RC. After multiple imputations, inverse probability of treatment weighting (IPTW) was used to account for potential selection bias. Multivariable logistic regression analysis was performed to evaluate the impact of NAC on pathologic complete response and downstaging at RC, while IPTW-adjusted Kaplan-Meier curves and Cox regression models were built to evaluate the impact of NAC on overall survival (OS).RESULTS: After IPTW-adjusted analysis, standardized differences between groups were less than 15%. A complete response (pT0N0) at final pathology was achieved in 94 (30%) patients receiving NAC and 9 (3%) patients undergoing upfront RC. Downstaging to non-muscle invasive disease (

View details for DOI 10.1111/bju.15289

View details for PubMedID 33152179